<DOC>
	<DOCNO>NCT00401544</DOCNO>
	<brief_summary>To deterime efficacy 500 μg 300 μg darbepoetin alfa administer subcutaneously ( SC ) every 3 week ( Q3W ) schedule , effect intravenous ( IV ) iron supplementation treatment anemia patient non-myeloid malignancy receive multicycle chemotherapy .</brief_summary>
	<brief_title>Darbepoetin Alfa With Without Intravenous ( IV ) Iron</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Iron-Dextran Complex</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<mesh_term>Dextrans</mesh_term>
	<criteria>Active non myeloid malignancy ( cies ) include lymphocytic leukemia Received chemotherapy expect receive least 8 additional week cyclic cytotoxic chemotherapy Anemia due chemotherapy ( screen Hgb &lt; = 10.0 g/dL ) least 18 year age screen Acute myelogenous leukemia ( AML ) , chronic myelogenous leukemia ( CML ) , myelodysplastic syndrome ( MDS ) Other underlie hematologic disorder , could cause anemia , non myeloid malignancy Active bleeding Severe , unstable , active chronic inflammatory disease ( eg ulcerative disease , peptic ulcer disease , rheumatoid arthritis ) Active , unstable systemic chronic infection Planned elective surgery study significant blood loss expect Unstable angina , uncontrolled cardiac arrhythmia Uncontrolled hypertension ( diastolic blood pressure &gt; 100 mmHg ) History pure red cell aplasia ( PRCA ) History deep venous thrombosis Known positive human immunodeficiency virus ( HIV ) test acquire immune deficiency syndrome ( AIDS ) status Any redbloodcell ( RBC ) transfusion within 28 day randomization and/or screen Currently receive thalidomide lenalidomide without prophylactic anticoagulant therapy Currently receive plan receive myeloablative radiation therapy Received bone marrow stem cell transplant 6 month prior screen plan study Received erythropoietic therapy within 28 day randomization and/or screen ( eg rHuEPO darbepoetin alfa ) Known sensitivity erythropoietic agent , investigational product excipients administer study Known sensitivity iron administration Pregnant breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>anemia</keyword>
	<keyword>chemotherapy induce anemia</keyword>
	<keyword>darbepoetin alfa</keyword>
	<keyword>cancer</keyword>
</DOC>